|
18 documents found matching cs:neurontin*.
|
|
of 2
Prev
Next
|
|
|
|
Showing 1-10 of 18 documents
|
1.
Neurontin (Gabapentin)
|
Document Date:
|
20001130
|
|
Author:
|
McCrorie, Hank|Katen, Karen
|
|
Search Terms in Context:
|
Sent: Thursday, November 30, 2000 7:00 PM
To: DL-AII_Field_Force
Cc: DL-Sales_VPs_AII; DL-Sales_Ops_AII; Katen, Karen L; Chapman, Chris; Evans, George (Ny-
Legal); Johnson, Rady Subject: NEURONTIN (GABAPENTIN)
MEMORANDUM
November 30, 2000
TO: U.S. PHARMACEUTICAL FIELD FORCE
FROM: Hank McCrorie
RE: Neurontin® (gabapentin)
cc: Karen Katen, Executive Vice President, PPG
As indicated by Karen Katen in her November 10th memorandum to PPG-US Marketing, Sales, and Medical senior management (see Attachment), a number of decisions have been made relevant to the promotion and marketing of Neurontin which appropriately respond to certain legal challenges we face. This memorandum is intended to further communicate those decisions relevant to PPG-US sales personnel, so that appropriate action can be taken within Pfizer's US sales operations to ensure their effective imple
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18t10
|
|
| |
2.
CALCULATION OF DAMAGES FOR THE NEURONTIN MDL CLASS PLAINTIFFS AND COORDINATED PLAINTIFFS (AETNA, GUARDIAN AND KAISER)
|
Document Date:
|
20080811
|
|
Author:
|
Hartman, Raymond
|
|
Search Terms in Context:
|
Declaration of Raymond S. Hartman
Calculation of Damages for the Neurontin MDL Class Plaintiffs and Coordinated Plaintiffs (Aetna, Guardian and Kaiser)
I. Qualifications
1. My name is Raymond S. Hartman. I am Director and President of Greylock McKinnon Associates (GMA), a consulting and litigation support firm located in Cambridge, Massachusetts. I have previously presented my qualifications in my August 2005 Declaration in this matter1 and do not repeat them here. An updated curriculum vitae and a listing of deposition and trial appearances is presented in Attachment A. My rate of compensation in this matter is $475.00 per hour. Materials cited in this Declaration appear in Attachment C.
II. Overview and Summary
2. I have been asked by counsel to the named Plaintiffs and the Classes to calculate the monetary value of damages. The MDL Classes and Subclasses are defined as follows:
"All private, non-governmental entities in the United States and its territories that paid or r
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18k10
|
|
| |
| 3.
Estimate of Units Paid for by Neurontin Endpayers that Resulted from Alleged Fraudulent Marketing by Defendants
|
| |
4.
REVISED SUPPLEMENTAL DECLARATION OF ILYAS J. RONA FILED IN SUPPORT OF PLAINTIFFS RENEWED MOTION FOR CLASS CERTIFICATION
|
Document Date:
|
20081006
|
|
Author:
|
Rona, Ilyas
|
|
Search Terms in Context:
|
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS
IN RE NEURONTIN MARKETING, SALES PRACTICES, AND PRODUCTS LIABILITY LITIGATION
THIS DOCUMENT RELATES TO: ) MDL Docket No. 1629
) Master File No. 04-10981
) Judge Patti B. Saris
ALL MARKETING AND ) Mag. Judge Leo T. Sorokin
SALES PRACTICES ACTIONS )
REVISED SUPPLEMENTAL DECLARATION OF ILYAS J. RONA FILED IN SUPPORT OF PLAINTIFFS' RENEWED MOTION FOR CLASS CERTIFICATION
I, Ilyas J. Rona, do hereby state and depose, the following:1
1. I am an attorney at the law firm Greene & Hoffman, P.C. and am duly admitted to practice law in the Commonwealth of Massachusetts and to appear before the United States District Court for the District of Massachusetts. All statements made herein are based on facts personally known or represented to me, and if called upon, I could testify competently thereto.
2.
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18u10
|
|
| |
5.
Re: ADA Symposium
|
Document Date:
|
20010426
|
|
Author:
|
Grogan, Christine
|
|
Search Terms in Context:
|
From: Grogan, Christine (Tina)
Sent: Thursday, April 26, 2001 4:10 PM
To: Hwang, Angela; Tyler, Lance
Cc: Glover, Craig; 'brooks@embryonic.com'
Subject: RE: ADA Symposium
Craig, I guess the solution would be to have Marta put the suggestion in the letter, we will send back to the review that IHR reps will have invites, (maybe a stipulation to only target glucotrol/viagra clients) Not sure it will go thorugh but we could try. I hate to disadvantate the other teams on this project.
-----Original Message-----
From: Hwang, Angela
Sent: Thursday, April 26, 2001 8:11 AM To: Tyler, Lance; Grogan, Christine (Tina) Subject: RE: ADA Symposium
Isn't it the grants committee who will review? Let me know when we have teh approval, Lance - our reps would be glad to distribute too
Thanks
-----Original Message-----
From: Tyler, Lance
Sent: T
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18h10
|
|
| |
6.
Neurontin Action Plan - POA2-2004
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
JfcMHxnvtlM. c4n±lxrw. Via*. - ~P0c42-200*l
2004 Goal_________________________________________________________________
• National Goal = Achieve $2.5 Billion and 15% growth in 2004
• Currently 104% of Budget, GAR = 98.77%. YTD Sales of $780 million with growth 19.7%
Market Overview_____________________________________________________________
• Neurontin weekly shares are trending up - bottomed in January after declining in 2003.
• Tablet business has increased from 32%> to 37% of Neurontin total.
• 75% of targeted PCPs now achieving at least 1800mg. PCPs still slowest to get there.
• Other AEDs growing faster than Neurontin in LTC (16% vs 59%)
• Eisai's new specialty team will promote Zonegran.
Strategies
• 2nd position Detail on every call
• Deliver Consistent 3 Step Message
• Grow LTC business
No calls on Psychs!!!!
Core Message
"NEURONTIN Is a Different Kind of Medication that provides Significant Reduction of the Burning, Stabbing, and Electric-Shock-Like Pa
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18i10
|
|
| |
7.
Expert Report of John Abramson
|
Document Date:
|
20080811
|
|
Author:
|
Abramson, John
|
|
Search Terms in Context:
|
EXPERT REPORT OF JOHN ABRAMSON, MD.
pgNbr=1
TABLE OF CONTENTS
I. OPINIONS.....................................................................................................................3
II. QUALIFICATIONS......................................................................................................5
III. OVERVIEW..................................................................................................................8
IV. SOURCES OF INFORMATION ABOUT PRESCRIPTION DRUGS
RELIED UPON BY MEDICAL DECISION MAKERS............................................11
A. THE IDEAL.....................................................................................................11
1. Evidence-Based Medicine and the double-blind placebo-controlled randomized trial.................................................................11
2. Continuing Medical Education............................................................12
3. Drug Re
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18v10
|
|
| |
8.
Advances in the preventive treatment of migranes
|
Document Date:
|
19990716
|
|
Author:
|
Biddle, Stephen
|
|
Search Terms in Context:
|
Annenberg Center for Health Sciences
AT EISENHOWER
39000 Bob Hope Drive
Rancho Mirage, California 92270-3298
¦:?%V ^"^O ^^'^^^^^^^^^¿Sw^i^^I
Jul î S!9 S '"
•,j — «W ™J
- I*
- J*
3 vI & 1 8 i ULJLJL° S T ». G ;¦: I *
Christy DeSantis Proworx
*"OOV7-.-sSlt Xi
ÍHiHJJ..
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18g10
|
|
| |
9.
Expert Report of Nicholas Jewell, Ph.D.
|
Document Date:
|
20080729
|
|
Author:
|
Jewell, Nicholas
|
|
Search Terms in Context:
|
EXPERT REPORT OF NICHOLAS P. JEWELL, Ph.D.
Executive Summary of Report
1. Backonja et al. report on the clinical efficacy of gabapentin on subjective pain scores as compared to placebo, based on a randomized controlled clinical trial of patients with diabetes mellitus suffering from painful diabetic neuropathy. These authors consider a potential bias in their results due to the significantly higher incidence of side effects among subjects exposed to gabapentin that might "unblind" an individual's treatment assignment, thereby distorting their subsequent pain reports. However, the authors did not find evidence of such a bias in a very simplistic analysis of two side effects analyzed separately. I have reanalyzed their data more thoroughly. The summary of my findings is that almost the entire apparent treatment effect reported in Backonja et al.1 disappears when data after the occurrence of treatment-related Central Nervous System (CNS) side effects is eliminated. I conclude that the trial provide
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18m10
|
|
| |
10.
Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain
|
Document Date:
|
20080810
|
|
Author:
|
Dickerson, Kay
|
|
Search Terms in Context:
|
08-10-08 1 of 57
Reporting and other biases in studies of Neurontin
for migraine, psychiatric/bipolar disorders,
nociceptive pain, and neuropathic pain
Kay Dickersin, MA, PhD
August 10, 2008
08-10-08 2 of 57
Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders,
nociceptive pain, and neuropathic pain
Table of Contents
Executive Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Qualifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1. Reporting biases in the dissemination of biomedical knowledge . . . . . . . . . . . . . . . . . . 7
1.1 The ethical and scientific imperative to communicate knowledge gained from
biomedical research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2 Reporting biases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx18r10
|
|
| |
|
Prev
Next
|
